Scientific Validation

Press Release

presse-conf-dengue-colegiomedicoPRESS RELEASE
The Colegio Médico de Beni [Beni Medical Association] and the Germán Busch Municipal Hospital communicate the following information for public release:

  1. Owing to the health emergency and social demand due to the dengue epidemic in our Department and in the entire country, and in view of the fact that there is no specific treatment to prevent and/or reduce the severity of the symptoms and complications of this disease, an interinstitutional effort was implemented to provide viable alternatives to this complex issue.
  2. On 5 and 6 February of this year will commence the interinstitutional health conference sponsored by the Colegio Médico del Beni, and among other conclusions, priority is being given to the development of a treatment protocol to perform follow-up on dengue cases at the Germán Busch Municipal Hospital, conscious of the difficult moments experienced by our country with a growing epidemic of dengue and encouraged by the international and also regional experience with treatments including the eubiotic drink VILAC PLUS, considering it to have immunostimulant and excellent antioxidant properties.
  3. It is with great pleasure that we are reporting to the public the satisfactory results obtained, which have been clinically substantiated and certified in laboratory tests. (more…)

Antituberculosis Association recommends Vilac Plus, especialy in case of HIV

tb_pongsiri_2008Antituberculosis Association Chiang Mai
Mae Hae District, Moung Chiang Mai
Chiang Mai 50200 Thailand

21 June 2008

To Whom it may concern,

As the capacity of the President of Antituberculosis Association Chiang mai, I would like to recommend Vilac Plus fermented Herbal plants from Thailand for the treatment of TB patients and also for HIV / AIDS with pulmonary tuberculosis as an opportunistic infection, the patient can recover very quickly within few weeks after therapy, since Vilac Plus is the immunebooster and also high potency antiinfective agents containg Lactobacillus, it should be trivial as the complimentaruy regimens comparing with the conventional treatment.

Your very Truly,

Pongsiri Prathnadi M.D.,FCCP,FICS

Professor and Doctor

President of Antituberculosis Association of Chiag Mai Thailand

Cervical Cancer – Clinical Trials

Evaluation of the effectiveness of the product the Vilac Plus® Eubiotic Drink G716/45 on Cancers Stage IIIB and IV.

Palliative treatment of advanced cervical cancer with radiotherapy and Thai herbal medicine as supportive remedy

Clinical trials HE480745 conducted at Srinagarind Public Hospital, Faculty of Medicine, Khon Kaen University, Thailand. Published in The Asean Journal of Radiology, September – December 2007.

Abstract

Objective

To evaluate the supportive effect of Thai herbal medicine, Vilac Plus (G716/45) on standard radiotherapy in comparison with historic control from the literature reports the results of treatment in stage IIIB-IV cervical cancer.

Patients and Methods

During the period of March 2003 to June 2005. Thirty patients in advanced cervical cancer stage IIIB-IV with poor performance status were treated by palliative radiotherapy in adjuvant with the Thai herbal tonic solution (Vilac Plus G716/45) daily dose 15-30 ml orally tid, pc as an additional supportive remedy.

Results

Thirty cases of patients in advanced cervical cancer stage IIIB-IV with poor performance status, the median age in stage IIIB, IVA, IVB were 50 years (range 41-73 years), 50.5 years (45 years, 58 years), 69 years (67 years, 71 years) respectively. The analysis were being categorized and performed on stages IIIB, IVA, IVA with bladder cancer and IVB reporting in corresponding number of cases/total subject (percentage) were 25/30 (83.33%), 2/30 (6.67%), 1/30 (3.33%) and 2/30 (6.67%) respectively. The median tumor size for stages IIIB, IVA and IVB were 5 cm (range 2-10 cm), 5 cm (4,6 cm) and 4 cm (2,6 cm) respectively. The pathological identification had been classified to be squamous cell carcinomas 21/30 (70.00%), adenocarcinomas 7/30 (23.33%), small cell carcinoma 1/30 case (3.33%) and clinically staging IIIB 1/30 case (3.33%). The median time interval between teletherapy and brachtytherapy was 22 days (range 7-41 days). Eventually, 84% of the stage IIIB cases were undergone by prolonged gap of more than 2 weeks of time interval between teletherapy and brachytherapy while the rest of the case (16%) received the optimal time gap of treatments. The initial complete response and partial response after 4-6 weeks of radiotherapy were 84% and 16% respectively. The patterns of failure in stage IIIB revealed in 16% with residual pelvic diseases (< 6 months), 3% with local pelvic recurrence (> 6 months) and 4% with distant metastases. Median follow-up period in stage IIIB was 22 months (range 2-48 months). Low radiation complications were noted, the severe radiation proctitis (grade 3) was found to be 3.33%. It was notable results in the declined BUN/Cr level in cervical cancer patients with underlying renal insufficiency/chronic renal failure patients treated by palliative radiotherapy and Thai herbal tonic solution as an additional supportive remedy had been observed in 2 cases of stage IIIB and 1 case of stage IVA with neither surgical intervention nor hemodialysis.

Conclusion

Our preliminary study in the treatment of advanced cases of Ca. Cervix with palliative radiotherapy and Thai herbal medicine had shown the evidence of initial complete regression of tumour with disappearance of foul smell discharge as high as 84% with low rate of local pelvic recurrence, low distant metastases and low rate of radiation complication. However, the study had a limitation on the number of cases and a short follow up period. Moreover, this treatment modality had shown the benefit on the declination of BUN/Cr level in some cases of those locally advanced stages III B-IV in chronic renal failure caused by chronic ureteric obstruction due to lateral spreading of the cancer pressing on both ureters, without neither surgical intervention nor hemodialysis. The declined BUN/Cr levels were the consequence of the relief of pressure effect on the ureters by the decreasing of the tumour volumes. Palliative radiotherapy with Thai herbal tonic as supportive remedy was safe, cost effective, in addition to the benefit of improval of quality of life without the toxicity of herbal medicine. Therefore, this combination of palliative radiotherapy together with Thai Herbal Medicine would be the alternative option for the palliative treatment of advanced cancer cases with poor performance status or in locally advanced cancer cases. Further studies should be performed in order to confirm this findings with statistical significant conclusion.

Montien PESEE M.D, Wichit KIRDPON Ph.D, Sukachart KIRDPON M.D, Anucha PUAPAIROJ M.D and Pongsiri PRATHNADI M.D

Download

Acute Oral Toxicity Test (Limit test) of “VILAC PLUS”

This report was submitted by the Thailand Institute of Scientific and Technological Research (TISTR) in october 2007.

Here is the report as a PDF file.

Brain Tumor – Clinical Trials

Evaluation of the effectiveness of the product the Vilac Plus® Eubiotic Drink G716/45 on Cancers Stage IIIB and IV.

Palliative treatment of advanced subependymal oligodendroglioma with radiotherapy and Thai herbal medicine as supportive remedy

Clinical trials HE480745 conducted at Srinagarind Public Hospital, Faculty of Medicine, Khon Kaen University, Thailand. Published in The Asean Journal of Radiology, September – December 2006.

Abstract

Objective

To evaluate the supportive effect of Thai herbal medicine, Vilac Plus complementarity to standard palliative radiotherapy in comparison with historic control from the literature reports in subependymal oligodendrogliomas.

Method

An inoperable subependymal oligodendroglioma in a 14 years old boy being treated by palliative radiotherapy and concurrent with Thai herbal medicine (Vilac Plus) as supportive remedy.

Result

The result revealed complete response of advanced subependymal oligodendroglioma. The patient shows good quality of life until now, 43 months after the diagnosis and starting the treatment. In addition, there is also omprovement of diabetes insipidus and still alive with Karnofsky’s performance status 100%. Currently the follow-up time is 43 months after the initial diagnosis and treatment (craniotomy and tumor biopsy).

Conclusion

The results of radiotherapy of an inoperable subependymal oligodendrogrlioma using Thai herbal medicine as an adjuvant remedy has been very satisfactory with good quality of life. This combination modality of treatment present a very promising and cost effectiveness therapy, leading to the confirmation of the concept of complementary approaches on cancer therapy.

Montien PESEE M.D, Wichit KIRDPON Ph.D, Anucha PUAPAIROJ M.D, Sukachart KIRDPON M.D and Pongsiri PRATHNADI M.D

Download

Lung Cancer – Clinical Trials

Evaluation of the effectiveness of the product the Vilac Plus® Eubiotic Drink G716/45 on Cancers Stage IIIB and IV.

Palliative treatment of advanced lung cancer with radiotherapy and thai herbal medicine as supportive remedy

Clinical trials HE480745 conducted at Srinagarind Public Hospital, Faculty of Medicine, Khon Kaen University, Thailand. Published in The Asean Journal of Radiology, September – December 2006.

Abstract

Objective

To evaluate the supportive effect of Thai herbal medicine, Vilac Plus (G716/45) on standard palliative radiotherapy in advanced stage IIIB-IV lung cancer compare with history control from the literature reports.

Patients and Methods

Thirteen patients in advanced lung cancer stage IIIB-IV with poor performance status were treated by palliative radiotherapy in adjuvant with the Thai herbal tonic solution (Vilac Plus G716/45).

Results

Thirteen patients (8 male, 5 female) in advanced stages lung cancer with poor performance status, stage IIIB 11 cases, stage IV 2 cases. Median age 66 years (range 44.4-83 years). The pathological diagnosis were 5 cases of squamous cell carcinoma, 2 cases of adenocarcinoma and 4 cases of clinically advanced lung cancer as of evidenced by computed tomography chest scan/chest X-ray. The results of treatment 4-6 weeks after radiotherapy revealed 76.92% (10/13 cases) of clinically improvement and 23.08% (3/13 cases) of clinically stable. Overall response rate was 46,15% (6/13) of partial response and 53.85% (7/13 cases) had shown stable diseases. Patterns of failure were found to be locally progressing 46.15% (6/13 cases) at the primary site, 30.77% (4/13 cases) at the locoregional, 23.08% (3/13 cases) at the locoregional with distant metastases. Median follow-up time is 18 months (range 7-50 months). Clinical benefit rate, evaluated at ≤ 15 months was 72.72%. However the median survival period analysis required longer follow-up and more detail assessment.

Conclusion

The results of this study are promising in the aspect of good quality of life and preferable because of the cost effectiveness to be used as an adjuvant for radiotherapy.

Montien PESEE M.D, Wichit KIRDPON Ph.D, Anucha PUAPAIROJ M.D, Sukachart KIRDPON M.D and Pongsiri PRATHNADI M.D

Download

KRL Test

Vilac Plus® Eubiotic Drink Antioxidant Capacity Analysis, laboratory test to assess the overall potential for defence against free radicals, Kirial International, Couternon, France – SPIRAL Laboratory, Patent: FR patent 2.642.526, US patent 5135850. Report N°0607002.

Summary and Conclusion

Our results underline that the eubiotic drink Vilac Plus presents in vitro an important antioxidant capacity, which increases with the dose of the product until a concentration of 50 ml by liter of the reaction medium.

At a concentration of 50 ml/L, the drink increases the resistance of the control blood to free radical aggression until 277.22 %. This 3.8 time increase in the control blood resistance induced by the product represents an antiradical effectiveness that is equivalent to 557.45 µmoles of Trolox ® or 320.92 µmoles of Gallic acid by liter of reaction medium. Thereby, a 50 ml drink of Vilac plus has an antioxidant activity which is equivalent to 557 µmoles of Trolox® or 321 µmoles of Gallic acid.

Philippe DURAND and Michel PROST

Download